• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens

tetano

Editor, Senior Moderator
Immunol Cell Biol. 2013 Sep 10. doi: 10.1038/icb.2013.46. [Epub ahead of print]
Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens.
Wei J, Waithman J, Xiao K, Oveissi S, Chen W.
Source

Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Austin Health, Melbourne, Victoria, Australia.
Abstract

Dendritic cells can take up exogenous tumor antigens and present their antigenic epitopes to CD8+ T cells (TCD8+), a process called cross-presentation. Cross-presentation is especially important in antitumor immunity because tumor cells, although carrying tumor antigens, do not activate naive T cells efficiently because of a lack of co-stimulatory molecules. Our group has recently shown that influenza A virus (IAV) infection of allogeneic cells lead to enhanced cross-priming of TCD8+ specific to cellular antigens. To develop this into a potential vaccine strategy, in this study, we have systematically investigated the numbers of allogeneic cells infected by IAV, IAV doses and their infectious activity, the length of in vitro infection and other associated factors. We have defined the optimal immune-enhancing conditions and we have also shown in vivo that such enhanced cross-priming did lead to enhanced tumor protection. The knowledge should be useful for developing more robust cancer vaccine.Immunology and Cell Biology advance online publication, 10 September 2013; doi:10.1038/icb.2013.46.

PMID:
24018533
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24018533
 
Back
Top Bottom